Latest news for Tirex (OTC:TXMC) Stock

Tirex Corp is engaged in the business of developing for sale, licensing or environmentally safe, patented, semi cryogenic turn key tire recycling system.

News

Intraday Update

Markets

Movers

Trading Ideas

ACRB

AMAT

AMKR

AMSWA

AQUA

ATKR

BARRF

BHFAP

BLDR

BMCH

CCMP

CELG

CETV

CHCT

CHTR

CMRE

COLD

CROX

THE CORETEC GROUP INC by The Coretec Group Inc.

CRTG

CSTM

DCOM

DLTR

ENTG

FBHS

FORM

GKPRF

GLIBA

GNRC

HPTN

INFO

INVH

INXN

IRET

JUMT

KLAC

KRNT

LBRDA

LBRDK

LEN-B

LGIH

LULU

MAMS

MDCO

MGDPF

NACG

NFBK

NVMI

ODFL

PACQ

PFSI

PLMR

PLUG

POOL

QRVO

RETA

REXR

RIOCF

Stocks That Hit 52-Week Highs On Thursday

Tirex Corp

Tirex

- FDA determined that it could not approve proposed revisions to the manufacturing testing limits requested through the Supplemental New Drug Application (sNDA) - 
- FDA provided recommendations and requested additional information to address the issues - 
- The Company will continue to supply ANNOVERA in compliance with the manufacturing testing limits approved in the original NDA -

BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXMD#NASDAQ">TXMD</a>) (&ldquo;TXMD&rdquo; or the &ldquo;Company&rdquo;), an innovative, leading women&rsquo;s healthcare company, today announced that the FDA determined that it could not approve revisions to certain manufacturing testing limits for ANNOVERA through the sNDA previously submitted by the Company. In its complete response letter, the FDA provided recommendations and requested additional information that could support approval of revisions to certain manufacturing testing limits. The Company will continue to manufacture and supply ANNOVERA under the existing approved specifications.

The sNDA requested minor revisions to the in vitro release testing specification for ANNOVERA to allow for normal commercial manufacturing variation. The Company submitted the proposed revisions to the manufacturing testing limits to allow it to efficiently and quickly increase supply to meet anticipated patient demand for ANNOVERA.

&ldquo;The Company will continue to manufacture and supply ANNOVERA under the existing specification and will work with the FDA to address their comments,&rdquo; said Hugh O&rsquo;Dowd, President of TherapeuticsMD.

ANNOVERA was approved by the FDA in August 2018 as the only long-lasting, reversible, procedure-free birth control.

Biotech

General

TXMC

TXMD

TherapeuticsMD Reports FDA 'determined that it could not approve proposed revisions to the manufacturing testing limits requested through the Supplemental New Drug Application'

Comments

Tirex

News

Latest news for Tirex (OTC:TXMC) Stock

Friday, December 10, 2021

Thursday, October 17, 2019

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga